Acute Progressive Cerebral Infarction Research Articles

Effect of Clopidogrel combined with aspirin in the treatment of acute progressive cerebral infarction: A retrospective single-center analysis

Effect of Clopidogrel combined with aspirin in the treatment of acute progressive cerebral infarction: A retrospective single-center analysis

Clinical Evaluation of miR-155 and miR-21 Alone and in Combination for Diagnosis of Acute Progressive Cerebral Infarction

Clinical Evaluation of miR-155 and miR-21 Alone and in Combination for Diagnosis of Acute Progressive Cerebral Infarction

Acute progressive large-area cerebral infarction caused by wasp sting: a case report

ABSTRACT Acute renal failure, multiple organ failure, and allergic reactions caused by wasp sting have been reported in many clinical reports, however, there are few reports on cerebral infarction due to wasp sting. We report a patient who developed acute progressive cerebral infarction after wasp stings, suffered from left-sided hemiplegia, clumsy speech, and left facial droop, only left the MRC grade 2 power and left conjugate gaze palsy after treatment. The MRA showed normal blood vessels. And the wasp sting was detected in head and right shoulder. We explored the mechanism by which the bee venom induced vasospasm and stimulated the superior cervical sympathetic ganglion leading to cerebral infarction. The treatment strategy is presented to provide experience for other clinicians.

Analysis of multiple factors involved in acute progressive cerebral infarction and extra- and intracranial arterial lesions.

In order to identify the potential factors involved in the development of acute progressive cerebral infarction (PCI), the association between potential risk factors and extra- and intracranial arterial lesions was investigated. A total of 608 patients underwent cerebral angiography to analyze the morphological characteristics between the PCI and NPCI groups. In addition, data from numerous cases of extra- and intracranial arterial lesions were collected and compared with the control groups, and the associations between the severity of arterial lesions and the potential influential factors were analyzed. In the blood vessels responsible for cerebral infarction, various degrees of atherosclerotic plaques and stenosis were observed. Age, high-density lipoprotein (HDL) levels, glycosylated hemoglobin and blood pressure affected the degrees of hardening, plaques and stenosis. Analysis of cerebral artery stenosis revealed that age, diabetes mellitus and plasma fibrinogen were risk factors for cerebral artery stenosis, while the HDL/low density lipoprotein ratio was a protective factor. Therefore, the results of the present study indicate that the lesions of blood vessels are a major pathological change in PCI and multiple factors are involved in the pathogenesis.

Clinical observation on the effet of edaravone combined with low-molecular-weight heparin on progressive cerebral infarction

Objective To study the clinical effect of low-molecular-weight heparin combined with edaravone in the treatment of progressive cerebral infarction.Methods 60 patients with acute progressive cerebral infarction in 72 hours were randomly divided into treatment group received edaravone combined low-molecular-weight heparin(n=30)and control group received low-molecular-weight heparin(n=30).The primary efficacy was evaluated by NIHSS(the National Institutes of Health Stroke Scale).ADL(Activities of daily living)and clinical effect.Results Our study showed that the score of NIHSS on 7th day post-therapy and 14th day post-therapy in treatment group was lower than that in control group(t=15.987 and 11.756,both P＜0.01).However,the score of ADL in the theatment group on 14th day post-therapy was higher than that of control group(t=62.56,P＜0.01).The overall clinical responserate of treatment group was higher than that of control group(x2=13.695,5.769,all P＜0.01).Conclusion Edaravone combined with low-molecular-weight heparin has remakable effect on the treatment of progressive cerebral infarcti. Key words: Brain infarction; Low-molecular-weight heparin; Edaravone

A controlled study on the treatment of acute progressive cerebral infarction by continuous anticoagulation with small doses of heparin

To discuss the treatment of acute progressive cerebral infarction by continuous anticoagulation with small doses of heparin. A prospective, randomized, and controlled clinical research was conducted. Three hundred and fifty-one patients were randomly divided into three groups. Group A (n=119) was treated with heparin, which was controlled by an infusion pump with a speed of 18 U×kg(-1)×h(-1) for 24 hours, and the dosage was regulated according to the changes in activated partial thromboplastin time (APTT) which was determined every 8 hours. Group B (n=115) was treated with intravenous drip of 12,500 U of heparin with a speed of 18 U×kg(-1)×h(-1) once a day. Group C (n=117) was treated with 5000 U of low-molecular-weight heparin calcium injection twice a day. After 14 days, nerve function defect according to the National Institutes of Heath stroke scale (NIHSS) score was determined, the adverse events (e.g. intracranial hemorrhage, subcutaneous ecchymosis, gingival bleeding, hematuria and occult blood in stools) were observed. After 6 months, the recurrence rate and Barthel index (BI) would be determined. The total efficiency in group A (95.80%) was significantly higher than that in group B (85.22%) and group C (85.47%). Recurrence rate in group A (1.68%) was significantly lower than group B (8.70%) and group C (8.33%) with significant differences (P<0.05 or P<0.01), while there was no significant difference between group B and group C (both P>0.05). The BI of group A (89.27±8.56) was significantly higher than group B (72.57±9.77) and group C (71.66±9.37) with significant difference (both P<0.01), while there was no significant difference between group B and group C (P>0.05). Adverse event rate in group A (5.88%) was slightly higher than that of group B (3.48%) and group C (4.27%), but the difference was not significant (both P>0.05). Continuous infusion of low dosage of heparin could significantly reduce neurologic impairment score in patients with progressive cerebral infarction, increase cure rate, reduce the recurrence rate, and raise the BI of patients, and it dose not increase the risk of intracranial and extracranial hemorrhage.

Study on curative effect of clopidogrel bisulfate combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction

Objective To explore the curative effects of clopidogrel bisulfate combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction. Methods 117 patients with progressive cerebral infarction were randomly divided into two groups, There were 62 patients in the treatment group and 55 patients in the control group. In the treatment group, clopidogrel bisulfate 300mg was apphed initial dose, followed by 75mg qd×13d and the low molecular weight Heparin 4000IU, twice a day,subcutaneous injection,for 7d; the control group were treated with oral enteric-coated aspirin 100mg, once a day. All of them were controlled with blood glucose, blood pressure, blood fat, dehydration and improved brain cells metabolism etc. Results The curative effects were compared between two groups, the treatment group was much better than that in the control group(P＜ 0.01) Conclusion Clopidogrel bisulfate combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction is effective and safe. Key words: Clopidogrel bisulfate; Low molecular weight heparin; Progressive brain infarction